Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.49 |
| ▸ | MPC2 | O95563 | 2/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21504846 | 0.87 | PPARG (0.52) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL24943391 | 0.84 | PPARG (0.68) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL936483 | 0.83 | PPARG (0.72) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL25832955 | 0.81 | PPARG (0.49) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL24050797 | 0.78 | PPARG (0.57) | PPARGMPC2CYP2C8CYP2C9NPC1 | |
| SCHEMBL8282070 | 0.77 | PPARG (0.47) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL24050788 | 0.77 | PPARG (0.55) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL21504803 | 0.77 | PPARG (0.71) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL25833061 | 0.77 | PPARG (0.55) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL21504834 | 0.76 | PPARG (0.52) | PPARGMPC2CYP2C8CYP2C9FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230013627-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20210361629-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2021-11-25 | — | — | US | disclosed |
| EP-3202401-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Octeta Therapeutics, LLC (US) | 2017-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361629-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | PPARD, FABP1, GOT2 | PPARG 4/4885MPC2 194/4885CYP2C8 361/4885 |
| US-20230013627-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | FABP1, HNF4A, PPARD | PPARG 6/4885MPC2 153/4885CYP2C8 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.